Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate versus neurofeedback for children with ADHD
IRCT20161122031016N2Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Islamic Azad University. Primary endpoints: Executive function and Externalizing behavior disorders. Started Apr 2022; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20161122031016N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20161122031016N2.